Zhuolun Song

Zhuolun Song

Auto-generated profile, based on publicly available information

Zhuolun Song

Division of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2020 in Hepatology
Verified
Journal Article
Closed access
PDF file
ZSZhuolun Song
Zhuolun Song
WCWei Chen
Wei Chen
DADipti Athavale
Dipti Athavale
XGXiaodong Ge
Xiaodong Ge
RDRomain Desert
Romain Desert
Natalia NietoNatalia Nieto
Natalia Nieto

1 October 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
HHHui Han
Hui Han
RDRomain Desert
Romain Desert
SDSukanta Das
Sukanta Das
ZSZhuolun Song
Zhuolun Song
DADipti Athavale
Dipti Athavale
Natalia NietoNatalia Nieto
Natalia Nieto

1 April 2023 in Hepatology
Verified
Journal Article
Closed access
RDRomain Desert
Romain Desert
WCWei Chen
Wei Chen
XGXiaodong Ge
Xiaodong Ge
RVRoselyne Viel
Roselyne Viel
HHHui Han
Hui Han
NNNatalia Nieto
Natalia Nieto
Background and Aims: HCC, the third leading cause of cancer-related death, arises in the context of liver fibrosis. Although HCC is generally poorly fibrogenic, some tumors harbor focal intratumor extracellular matrix (ECM) deposits called “fibrous nests.” To date, the molecular composition and clinical relevance of these ECM deposits have not been fully defined. Approach and Results: We performed quantitative matrisome analysis by tandem mass tags mass spectrometry in 20 human cancer specific matrisome (HCCs) with high or low-grade intratumor fibrosis and matched nontumor tissues, as well as in 12 livers from mice treated with vehicle, carbon tetrachloride, or diethylnitrosamine. We found 94 ECM proteins differentially abundant between high and low-grade fibrous nests, including interstitial and basement membrane components, such as several collagens, glycoproteins, proteoglycans, enzymes involved in ECM stabilization and degradation, and growth factors. Pathway analysis revealed a metabolic switch in high-grade fibrosis, with enhanced glycolysis and decreased oxidative phosphorylation. Integrating the quantitative proteomics with transcriptomics from HCCs and nontumor livers (n = 2,285 samples), we identified a subgroup of fibrous nest HCCs, characterized by cancer-specific ECM remodeling, expression of the WNT/TGFB (S1) subclass signature, and poor patient outcome. Fibrous nest HCCs abundantly expressed an 11-fibrous-nest–protein signature, associated with poor patient outcome, by multivariate Cox analysis, and validated by multiplex immunohistochemistry. Conclusions: Matrisome analysis highlighted cancer-specific ECM deposits, typical of the WNT/TGFB HCC subclass, associated with poor patient outcomes. Hence, histologic reporting of intratumor fibrosis in HCC is of clinical relevance.

27 April 2023 in Hepatology
Verified
Journal Article
Closed access
WCWei Chen
Wei Chen
YSYameng Sun
Yameng Sun
SCShuyan Chen
Shuyan Chen
XGXiaodong Ge
Xiaodong Ge
WZWen Zhang
Wen Zhang
HYHong You
Hong You
Background & Aims: Excessive deposition and crosslinking of extracellular matrix increases liver density and stiffness, promotes fibrogenesis, and increases resistance to fibrinolysis. An emerging therapeutic opportunity in liver fibrosis is to target the composition of the extracellular matrix or block pathogenic communication with surrounding cells. However, the type and extent of extracellular changes triggering liver fibrosis depend on the underlying etiology. Our aim was to unveil matrisome genes not dependent on etiology, which are clinically relevant to liver fibrosis. Approach & Results: We used transcriptomic profiles from liver fibrosis cases of different etiologies to identify and validate liver fibrosis-specific matrisome genes (LFMGs) and their clinical and biological relevance. Dysregulation patterns and cellular landscapes of LFMGs were further explored in mouse models of liver fibrosis progression and regression by bulk and single-cell RNA sequencing. We identified 35 LFMGs, independent of etiology, representing an LFMG signature defining liver fibrosis. Expression of the LFMG signature depended on histological severity and was reduced in regressive livers. Patients with liver fibrosis, even with identical pathological scores, could be subclassified into LFMGLow and LFMGHigh, with distinguishable clinical, cellular, and molecular features. Single-cell RNA sequencing revealed that microfibrillar-associated protein 4+ activated HSC increased in LFMGHigh patients and were primarily responsible for the LFMG signature expression and dysregulation. Conclusions: The microfibrillar-associated protein 4+ -activated HSC-derived LFMG signature classifies patients with liver fibrosis with distinct clinical and biological characteristics. Our findings unveil hidden information from liver biopsies undetectable using traditional histologic assessments.

15 June 2019 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
NMNan Ma
Nan Ma
ZSZhuolun Song
Zhuolun Song
CDChong Dong
Chong Dong
CSChao Sun
Chao Sun
XMXingchu Meng
Xingchu Meng
ZSZhongyang Shen
Zhongyang Shen

12 September 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
ZSZhuolun Song
Zhuolun Song
STSarah Tsou
Sarah Tsou
FMFriederike Martin
Friederike Martin
MKMukhammad Kayumov
Mukhammad Kayumov
YXYao Xiao
Yao Xiao
STStefan G. Tullius
Stefan G. Tullius
Immunosenescence, a state marked by immune dysfunction, chronic low-grade inflammation, and impaired pathogen defense, is accelerated in CKD. CKD promotes systemic inflammation through the accumulation of uremic toxins, oxidative stress, and dysregulated immune signaling, all driving premature aging of both innate and adaptive immune cells. These mechanisms result in dysregulated immune activation and impaired surveillance, thereby aggravating kidney damage and increasing the risk for comorbidities. Despite removing uremic toxins, dialysis may further accelerate immunosenescence by exposing immune cells to oxidative and antigenic stress, inducing telomere shortening and T-cell exhaustion. Kidney transplantation can partially reverse CKD-induced immunosenescence by restoring kidney function. Commonly used immunosuppressive agents, however, may further promote immunosenescence by impairing thymic function, depleting naïve T cells, and suppressing natural killer cell activity. However, mammalian target of rapamycin (mTOR) inhibitors have shown anti-aging effects by promoting autophagy and inhibiting proinflammatory pathways. Therapeutic strategies targeting immunosenescence in CKD have been gaining momentum. Senotherapeutics can eliminate senescent cells and reduce senescence-associated secretory phenotype (SASP)–mediated inflammation. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, caloric restriction, microbiome modulation, mesenchymal stem cell therapies, and KRTs also offer the potential to slow accelerated immunosenescence as a consequence of CKD. Here, we provide a comprehensive overview of the mechanisms linking CKD and immunosenescence, along with emerging therapeutic strategies that have the potential to target premature aging.